Hanmi Pharm. Co., Ltd. (128940.KS)
KRW 269500.0
(-1.46%)
KRW 269500.0
(-1.46%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1490.88 Billion KRW | 11.97% |
| 2022 | 1331.54 Billion KRW | 10.67% |
| 2021 | 1203.18 Billion KRW | 11.84% |
| 2020 | 1075.85 Billion KRW | -3.39% |
| 2019 | 1113.64 Billion KRW | 9.62% |
| 2018 | 1015.96 Billion KRW | 10.84% |
| 2017 | 916.58 Billion KRW | 3.84% |
| 2016 | 882.72 Billion KRW | -33.0% |
| 2015 | 1317.53 Billion KRW | 73.07% |
| 2014 | 761.27 Billion KRW | 4.27% |
| 2013 | 730.13 Billion KRW | 8.33% |
| 2012 | 674 Billion KRW | 11.19% |
| 2011 | 606.19 Billion KRW | 79.68% |
| 2010 | 337.38 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 378.13 Billion KRW | -6.33% |
| 2024 Q3 | 362.07 Billion KRW | -4.25% |
| 2024 Q1 | 403.68 Billion KRW | -4.42% |
| 2023 Q2 | 342.73 Billion KRW | -5.11% |
| 2023 Q3 | 364.61 Billion KRW | 6.38% |
| 2023 Q4 | 422.35 Billion KRW | 15.84% |
| 2023 FY | 1490.88 Billion KRW | 11.97% |
| 2023 Q1 | 361.18 Billion KRW | 2.85% |
| 2022 FY | 1331.54 Billion KRW | 10.67% |
| 2022 Q4 | 351.17 Billion KRW | 2.64% |
| 2022 Q3 | 342.14 Billion KRW | 7.9% |
| 2022 Q1 | 321.12 Billion KRW | -8.37% |
| 2022 Q2 | 317.09 Billion KRW | -1.26% |
| 2021 Q2 | 279.3 Billion KRW | 3.33% |
| 2021 Q1 | 270.31 Billion KRW | -2.52% |
| 2021 Q4 | 350.47 Billion KRW | 15.64% |
| 2021 Q3 | 303.08 Billion KRW | 8.51% |
| 2021 FY | 1203.18 Billion KRW | 11.84% |
| 2020 Q2 | 243.41 Billion KRW | -15.54% |
| 2020 Q3 | 266.93 Billion KRW | 9.66% |
| 2020 Q4 | 277.3 Billion KRW | 3.89% |
| 2020 FY | 1075.85 Billion KRW | -3.39% |
| 2020 Q1 | 288.2 Billion KRW | -4.85% |
| 2019 Q2 | 270.39 Billion KRW | -1.55% |
| 2019 Q4 | 302.9 Billion KRW | 14.0% |
| 2019 FY | 1113.64 Billion KRW | 9.62% |
| 2019 Q1 | 274.64 Billion KRW | -6.5% |
| 2019 Q3 | 265.7 Billion KRW | -1.73% |
| 2018 Q2 | 241.3 Billion KRW | -1.78% |
| 2018 FY | 1015.96 Billion KRW | 10.84% |
| 2018 Q4 | 293.72 Billion KRW | 24.85% |
| 2018 Q3 | 235.25 Billion KRW | -2.51% |
| 2018 Q1 | 245.67 Billion KRW | 5.61% |
| 2017 Q4 | 232.63 Billion KRW | 2.22% |
| 2017 FY | 916.58 Billion KRW | 3.84% |
| 2017 Q2 | 222.81 Billion KRW | -4.59% |
| 2017 Q1 | 233.54 Billion KRW | 35.72% |
| 2017 Q3 | 227.57 Billion KRW | 2.14% |
| 2016 FY | 882.72 Billion KRW | -33.0% |
| 2016 Q1 | 256.37 Billion KRW | -56.54% |
| 2016 Q2 | 234.54 Billion KRW | -8.52% |
| 2016 Q4 | 172.08 Billion KRW | -21.68% |
| 2016 Q3 | 219.72 Billion KRW | -6.32% |
| 2015 Q2 | 244.47 Billion KRW | 13.84% |
| 2015 FY | 1317.53 Billion KRW | 73.07% |
| 2015 Q1 | 214.74 Billion KRW | 1.55% |
| 2015 Q4 | 589.93 Billion KRW | 119.82% |
| 2015 Q3 | 268.37 Billion KRW | 9.78% |
| 2014 Q1 | 184.11 Billion KRW | -5.08% |
| 2014 Q4 | 211.47 Billion KRW | 17.92% |
| 2014 Q3 | 179.33 Billion KRW | -3.76% |
| 2014 FY | 761.27 Billion KRW | 4.27% |
| 2014 Q2 | 186.35 Billion KRW | 1.21% |
| 2013 Q4 | 193.97 Billion KRW | 4.18% |
| 2013 Q1 | 170.3 Billion KRW | -1.93% |
| 2013 Q3 | 186.19 Billion KRW | 3.63% |
| 2013 Q2 | 179.66 Billion KRW | 5.5% |
| 2013 FY | 730.13 Billion KRW | 8.33% |
| 2012 Q4 | 173.65 Billion KRW | 2.29% |
| 2012 FY | 674 Billion KRW | 11.19% |
| 2012 Q2 | 185.42 Billion KRW | 27.74% |
| 2012 Q1 | 145.16 Billion KRW | 0.0% |
| 2012 Q3 | 169.76 Billion KRW | -8.45% |
| 2011 Q3 | 125.21 Billion KRW | -4.94% |
| 2011 Q1 | 126.9 Billion KRW | 0.0% |
| 2011 FY | 606.19 Billion KRW | 79.68% |
| 2011 Q2 | 131.72 Billion KRW | 3.81% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 FY | 337.38 Billion KRW | 0.0% |
| 2010 Q3 | 150.76 Billion KRW | 0.0% |
| 2010 Q4 | - KRW | -100.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -986.577% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | -31.704% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | -133.518% |
| HANDOK Inc. | 522.74 Billion KRW | -185.206% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -1001.321% |
| Yuhan Corporation | 1858.98 Billion KRW | 19.801% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | -124.538% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -2769.572% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -1005.099% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -302.358% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -1582.839% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -779.23% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -564.22% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -986.577% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -1810.091% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -886.878% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -1606.531% |
| JW Holdings Corporation | 928.07 Billion KRW | -60.644% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | -148.168% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 10.693% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -99.176% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -644.593% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -724.776% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -659.317% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | -105.245% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -986.577% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 1.556% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | -8.402% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -99.176% |
| Yuhan Corporation | 1858.98 Billion KRW | 19.801% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | -87.601% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -534.684% |
| Suheung Co., Ltd. | 594.56 Billion KRW | -150.752% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -99.176% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -410.353% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -434.477% |
| CKD Bio Corp. | 160.35 Billion KRW | -829.755% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | -182.927% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -312.864% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -547.105% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -644.593% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | -69.461% |
| Boryung Corporation | 859.62 Billion KRW | -73.435% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -1083.918% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -302.358% |
| JW Lifescience Corporation | 206.86 Billion KRW | -620.722% |